Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00634972 · ClinicalTrials.gov registry record · Phase 4
Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity
A Phase 4 study, sponsored by University of South Alabama.
- Terminated
- Registry status
- Phase 4
- Development phase
- 83
- Enrollment target
NCT00634972: Clinical Trial Phase 4 study, sponsored by University of South Alabama.
NCT00634972 is a Phase 4 study that was terminated before completion, run by University of South Alabama. The registered enrollment target is 83 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00634972, a Phase 4 study, was terminated before completion, sponsored by University of South Alabama.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 83 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or decrease its severity.In this study ACULAR will be compared to a placebo (artificial tear). The hypothesis would be that ACULAR treatment will decrease the incidence of moderate to severe ROP (grade II and above)by 50%.
Interventions
- DRUG placebo
- DRUG ACULAR
- DRUG REFRESH TEARS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 83 participants |
| Start Date | 2005-11 |
| Est. Completion | 2008-08 |
| Phase | Phase 4 |
Why NCT00634972 stopped before completion
NCT00634972 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 83 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (84% lower).
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00634972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00634972 about?
NCT00634972 is a clinical study titled "Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity". The purpose of this study is to test whether ACULAR, a nonsteroidal anti-inflammatory eye drop medication, can prevent the development of retinopathy of prematurity (ROP) and/ or decrease its severity.In this study ACULAR will be compared to a placebo (artificial tear). The hypothesis would be that...
What is the current status of trial NCT00634972?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 83 participants. The study started on 2005-11. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00634972?
The interventions under investigation include: placebo (DRUG), ACULAR (DRUG), REFRESH TEARS (DRUG).
Who is sponsoring clinical trial NCT00634972?
This trial is sponsored by University of South Alabama, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00634972's enrollment target sits among peer trials
83 937th of 2000 higher than 1,062 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02974647 · 83 participants · Phase 2
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
- NCT03919292 · 83 participants · Phase 1
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
- NCT04626674 · 83 participants · Phase 1
A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)
- NCT05277168 · 83 participants · Phase 1
A Trial TO Evaluate THE Safety, Tolerability, Pharmacokinetics, AND Efficacy OF Shr-a1904 IN Subjects With Advanced Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia